GeneDx Holdings Corp. (NASDAQ:WGS) issued a bullish outlook for 2026 on Monday, forecasting revenue to exceed the half-billion-dollar milestone as the company’s pivot to high-margin exome and genome sequencing gains unprecedented traction.
The Gaithersburg, Maryland-based genomics leader expects 2026 revenue between $540 million and $555 million, representing a robust expansion from its preliminary 2025 total of $427 million.
The outlook is underpinned by an anticipated 33% to 35% growth in its core exome and genome business—the high-complexity testing segment that has become the company's primary engine for profitability.
For the recently concluded 2025 fiscal year, GeneDx reported preliminary revenue of $427 million, with its exome and genome revenue jumping 54% year-over-year.
The fourth quarter alone saw revenue of $121 million, as volume for its most advanced tests accelerated to a 34.3% growth rate.
The company also maintained an industry-leading adjusted gross margin of 71%, signaling that its scale is successfully offsetting the costs of rapid market expansion.
"In 2025, GeneDx continued its journey of transforming the standard of pediatric care by accelerating the use of genomics to the earliest moment families need answers," CEO Katherine Stueland said in a statement.
The company enters 2026 with $172 million in cash and a clear path toward positive adjusted net income, a milestone that has separated it from many of its peers in the clinical diagnostics space.